1623 Capital LLC Ultragenyx Pharmaceutical Inc. Transaction History

1623 Capital LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$39.96 - $66.14 $57,622 - $95,373	-1,442 Reduced 19.94%	5,789 $240,000
Q2 2022 Aug 12, 2022	BUY	$45.8 - $85.4 $145,964 - $272,169	3,187 Added 78.81%	7,231 $431,000
Q1 2022 May 13, 2022	SELL	$62.2 - $84.4 $39,372 - $53,425	-633 Reduced 13.53%	4,044 $294,000
Q3 2021 Nov 12, 2021	BUY	$77.92 - $102.4 $70,128 - $92,160	900 Added 23.83%	4,677 $422,000
Q2 2021 Aug 13, 2021	BUY	$92.19 - $115.71 $76,056 - $95,460	825 Added 27.95%	3,777 $360,000
Q1 2021 May 14, 2021	BUY	$106.9 - $167.73 $315,568 - $495,138	2,952 New	2,952 $336,000

325

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.14B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of 1623 Capital LLC, based on Form 13F filings with the SEC.

Stay updated on 1623 Capital LLC with notifications on news.